Market evolution: Syringes (CN 901831) — 2015–2025

Introduction

This report examines the evolution of EU external trade in syringes, with or without needles, used in medical, surgical, dental or veterinary sciences (Combined Nomenclature code 901831) over the period 2015–2025. Over this decade, the EU's syringe market underwent a profound transformation: total trade values more than doubled, the Union shifted from a marginal net exporter to a significant net importer, and pandemic-era shocks reconfigured supply chains and pricing structures. Drawing on EU-level trade data, this analysis identifies three overarching dynamics — the erosion of EU self-sufficiency, the catalytic role of the COVID-19 pandemic, and a structural reorientation of trade partnerships — and assesses their implications for the European medical devices sector.

1. The Erosion of EU Self-Sufficiency in Syringe Production

The EU swung from slight net exporter to substantial net importer

At the start of the period, the EU ran a modest trade deficit in syringes of €91.1 million, with net import reliance standing at −4.8% — meaning the bloc was nearly self-sufficient and even a slight net exporter in volume terms. By 2025, this figure had swung to +23.3%, a shift of nearly 589 percentage points, and the trade deficit had widened to €264.4 million (peaking at −€553.0 million at the worst point). This trajectory indicates a structural dependence on external syringe supply that did not exist a decade ago.

Import growth outpaced export growth in both value and volume

Source: General Overview — Trade

Import volumes grew by 49.6% while export volumes grew by only 32.4%, widening the structural gap. On the value side, imports surged by 115.2% versus 105.8% for exports. Notably, EU export unit values (€36,958/t in 2025) exceeded import unit values (€30,649/t), suggesting the EU specialises in higher-value syringe products — yet this premium has not been sufficient to offset the growing import volume deficit.

Domestic production volumes collapsed even as production values surged

EU production data reveals a striking paradox: the number of syringes produced in the EU fell from 12.4 billion pieces to 7.5 billion (−39.6%), while the total production value rose from €690 million to €1.8 billion (+160.9%). This implies a dramatic increase in average unit production value, likely reflecting a product mix shift towards higher-margin, specialised devices (e.g., safety-engineered or prefilled syringes) and away from mass-market disposable plastic syringes, where Asian producers dominate on cost.

Trade openness intensified across all dimensions

The EU's trade intensity rose from 68.6% to 88.7%, while export propensity climbed from 53.3% to 76.5%. These increases show that the EU syringe sector has become deeply integrated into global value chains — both importing more inputs and finished products and exporting a greater share of its own output. While this integration reflects competitive advantages in certain segments, it also heightens exposure to external supply disruptions.

2. The Pandemic Shock: COVID-19 as a Structural Turning Point

A massive price shock in Chinese imports to the EU marked the 2021 crisis peak

The data reveals a dramatic price shock in EU syringe imports from China centred on 2021: the abnormality score reached 104.5 (indicating an extreme outlier), with a year-on-year price shift of +133.8%. China's share of EU import value at that point was 12.7%. This shock reflects the global scramble for medical supplies during the mass vaccination campaigns of 2021, when demand for syringes spiked and supply chains were strained. Taiwan also exhibited extreme import volatility (coefficient of variation: 0.74), consistent with opportunistic or emergency sourcing patterns during the pandemic.

Export price shocks signalled demand from non-traditional markets

On the export side, the most notable shock events include a +242.9% price shift in exports to Canada in 2022 (abnormality: 45.9) and a +64.7% shift in exports to Australia in 2021 (abnormality: 14.2). These anomalies suggest that EU exporters were able to capitalise on global demand surges, channelling products towards markets willing to pay premium prices during acute shortages.

Post-pandemic prices never returned to pre-2020 levels

A critical finding is the ratchet effect on unit prices. EU import prices rose from €21,312/t in 2015 to a peak of €32,760/t before settling at €30,649/t in 2025 — a net increase of +43.8%. Similarly, export prices climbed from €23,782/t to €36,958/t (+55.4%). The product breakdown shows that plastic syringes (CN 90183110) saw their import unit price rise from €14,982/t to €25,017/t (+67.0%), while non-plastic syringes (CN 90183190) rose from €33,661/t to €49,255/t (+46.3%). This persistent elevation suggests a structural repricing of the market, driven by higher raw material costs, regulatory compliance costs (e.g., EU Medical Device Regulation), and a lasting shift in the product mix towards higher-specification items.

Plastic syringes dominate volumes but non-plastic syringes drove export growth

The segment breakdown reveals divergent trends between the two subcategories:

Plastic syringes account for the overwhelming majority of trade by volume, and their import volumes surged by 73.7%. Non-plastic syringe imports were essentially flat. However, non-plastic syringe exports exploded by +216.8% in volume — from 3,309t to 10,490t — even as their export unit price fell from €95,883/t to €65,752/t (−31.4%). This suggests EU manufacturers scaled up exports of glass or specialty syringes aggressively, accepting lower per-unit prices in exchange for volume, likely to capture growing global demand for glass syringes used in vaccine delivery and biologics.

3. A Reconfigured Map of Trade Partnerships

Switzerland and Taiwan emerged as dominant new import sources

The most dramatic shifts in EU import partnerships over the decade came from Switzerland and Taiwan:

Switzerland's explosive growth (+282.8%) likely reflects both the presence of major medical device companies (e.g., Becton Dickinson and other multinationals with Swiss operations) and the re-routing of supply chains through Swiss intermediaries. Taiwan's even more dramatic rise (+544.4%) is consistent with the island's growing role as a precision medical device manufacturer and a beneficiary of supply chain diversification away from mainland China. The Philippines, once a niche supplier, saw its exports to the EU virtually disappear (−82.8%).

The United States became the EU's most important single trade partner in both directions

The US consolidated its position as the EU's largest export destination (€409.1M in 2025, up from €106.7M, +283.3%) and second-largest import source (€463.7M, +41.3%). This bilateral intensification reflects deep integration between European and American medical device ecosystems — with cross-border manufacturing, contract manufacturing, and multinational corporate structures driving flows in both directions. The US export growth of +283.3% was the strongest among all EU export destinations.

EU export concentration increased as the market consolidated around fewer, larger partners

The Herfindahl-Hirschman Index (HHI) for EU exports by value rose from 910 to 1,302 (+43.1%), moving from a low-concentration regime to a moderate one. This indicates that EU syringe exports became more focused on a smaller number of destination markets — particularly the US, Switzerland, and China. Import concentration by value, meanwhile, declined modestly from 2,278 to 2,131 (−6.4%), indicating a slight diversification of sourcing, though the market remained moderately concentrated.

Within the EU, Germany, France, and Italy dominate but Austria and the Netherlands grew fastest

Looking at intra-EU specialisation in 2025, France (RSCA: 0.419), Hungary (0.407), Belgium (0.265), Denmark (0.259), and Italy (0.174) are the most specialised EU producers/exporters of syringes. At the other end, Greece, Lithuania, Croatia, Latvia, and Romania show negligible specialisation (RSCA close to −1.0), indicating these Member States are almost entirely import-dependent.

Among the top EU-27 importers, Austria's imports surged from €7.9M to €118.5M (+1,402%) — the most dramatic growth of any Member State — while the Netherlands' imports more than doubled (+144.0%). On the export side, Italy's exports to non-EU markets grew from €50.6M to €316.7M (+526.3%), overtaking Belgium and approaching Germany's level, reflecting Italy's strong position in the medical devices manufacturing cluster.

Conclusion

The EU syringe market (CN 901831) underwent a fundamental transformation between 2015 and 2025. The bloc moved from near self-sufficiency to a position of significant import reliance (+23.3% net import reliance), even as total trade values more than doubled. The COVID-19 pandemic acted as a structural inflection point: it triggered extreme price shocks (notably a +133.8% spike in Chinese import prices in 2021), permanently elevated market prices, and accelerated a product-mix shift towards higher-value items — EU production volumes fell by 39.6% while production values rose by 160.9%. Geographically, the trade map was redrawn: Switzerland and Taiwan emerged as major import sources, the United States consolidated as the EU's dominant bilateral partner in both directions, and export concentration intensified. Within the EU, a core of specialised producing nations (France, Germany, Italy, Belgium, Hungary, Denmark) drives the sector, while most smaller Member States remain almost entirely dependent on imports. Looking ahead, the EU's growing external dependence for a critical medical consumable — combined with persistently elevated unit prices and moderate supply-chain concentration — warrants continued attention from a strategic autonomy perspective.